| |
Tuesday, December 3, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now.
|
|
Today’s Big NewsNov 20, 2024 |
|
Wednesday, December 4, 2024 | 11am ET / 8am PT Designing nanodevices that can change shape and function in response to molecular signals is a key objective in protein design, paving the way for the development of switchable nanomaterials, triggerable drug-delivery systems, and molecular motors. Join us for a deep dive into the recent progress in designing and characterizing a diverse range of switchable protein assemblies. Register now.
|
|
| By Gabrielle Masson Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own Chris Boshoff, M.D., Ph.D., for the job and prompting a domino-effect of leadership changes. |
|
|
|
By Fraiser Kansteiner At this week’s meeting of the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee, panelists will be tasked with debating two questions around Andexxa’s safety and efficacy. Andexxa, which won an accelerated approval back in 2018, is a recombinant protein that binds to factor Xa inhibitors to reverse their anticoagulant effects. |
By Darren Incorvaia Viking Therapeutics has unveiled the final results of its phase 2b VOYAGE trial of oral small molecule VK2809 in metabolic dysfunction associated steatohepatitis (MASH). At the 52-week mark, the drug reduced liver fat content by an average of 37% to 55% compared to baseline, with all treatment arms showing statistically significant improvements compared to placebo. |
By Conor Hale With a new smartphone app clearance from the FDA, Medtronic said it has all the pieces necessary to deliver a complete diabetes management system. |
|
Thursday, December 5, 2024 | 1pm ET / 10am PT Learn how to leverage comprehensive patient journeys to improve targeting, understand unmet needs, and optimize your competitive strategy with real-world evidence that sees what others can’t. Register now to gain a competitive edge by evolving beyond traditional, limited datasets and unlock a deeper understanding of patient and physician decision-making.
|
|
By Kevin Dunleavy Johnson & Johnson and Merck are laying off workers in China, according to a story from Bloomberg which cites reports from Chinese news outlets. |
By Nick Paul Taylor Neurology patient groups have chided the pharma industry for investing too little into treating disorders of the nervous system. The call for more spending rang out from a survey, which found neurology patient groups are less satisfied with the current level of investment than their peers in other therapeutic areas. |
By Gabrielle Masson Investor confidence may be returning, with biopharma venture funding, deal value and exit activity all rising in 2024’s third quarter compared to the second. |
By Zoey Becker The latest nod positions Bimzelx to go head-to-head with Novartis' Cosentyx in the hidradenitis suppurativa market. |
By Fraiser Kansteiner Samsung Biologics said it inked a series of production pacts with an unnamed European pharma in a tie-up worth a total of $668 million. Samsung’s latest undertaking, which will see the CDMO provide manufacturing services to its client through 2031, brings the company’s cumulative new contract value this year to more than $4 billion. |
By James Waldron With President-elect Trump’s incoming administration having suggested it could create a national bitcoin reserve, a selection of biotechs have this morning announced their own plans to each create stockpiles of the decentralized digital currency. |
By Andrea Park With backing from Gilead, a group of cancer support organizations has unveiled the Black TNBC Sanctuary, a website equipped with resources about triple-negative breast cancer. |
By Darren Incorvaia Novartis is looking to edit the genomes of patient T cells without the immune cells ever needing to leave the body. To develop this next generation of in vivo T cell therapy, the Big Pharma has bought into Minnesota-based Vyriad’s suite of lentivirus vectors. |
By Fraiser Kansteiner Grifols’ board of directors on Tuesday rebuffed private equity firm Brookfield’s potential 6.45 billion euro buyout offer, recommending management reject the deal that it argues “significantly undervalues the company’s fundamental prospects and its long-term potential.” |
By Nick Paul Taylor Ferrer is using Pulmonary Hypertension Awareness Month to sound the alarm about the shortcomings of the current pathways for diagnosing and treating the blood pressure condition. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we explore a neuroscientist's alleged misconduct and its impact on the future of neurodegenerative disease research. |
|
|---|
|
|
|
Tuesday, December 10, 2024 | 12pm ET / 9am PT Mammalian synthetic biology has shown that key principles of biological regulation can be rewritten to control gene expression and produce complex, cellular behaviors. Recently, these core principles have now been applied at the protein level. Join us to learn about these latest approaches, and what the mean for cancer biology, immunology, and neuroscience. Sign up now!
|
|
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperUnlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
